演題概要

2C-S-1001

PDF

イメージング質量分析のグローバルガイドライン策定に向けて～医薬品の研究開発への活用を目指したグローバルサーベイの結果～

(¹JAIMS・ ²IMSS)
^o田中由香里¹・ Solon, Eric²・ Groseclose, Reid²・ Ho, Stacy²・ 田中広治¹・ 中田直之¹・ Linehan, Stefan²・ 西舘正修¹・ 横井宏之¹・ 渡辺健一¹・ 浦崎葉子¹・ 石田知己¹・ 鍛冶秀文¹・ 小松里香¹・ 吉田賢二¹・ 山崎浩史¹・ 齊藤公亮¹・ 斎藤嘉朗¹

Imaging mass spectrometry (IMS) has emerged as a powerful technology in the pharmaceutical industry with broad potential to enhance the discovery and development of new medicines. As with all new technologies used to support the discovery and development of new pharmaceuticals, scientists must develop, validate, and establish best practices to assure that the integrity of the data obtained supports new drug registration. The Imaging Mass Spectrometry Society (IMSS, leader: Eric Solon) and the Japan Association for Imaging Mass Spectrometry (JAIMS, leader: Yukari Tanaka) are conducting a thorough survey of IMS scientists, data analysts/users, project managers/leaders, and pharmaceutical compliance specialists who are currently using IMS techniques in support of their drug discovery and development efforts and/or who plan to use such tools as best practices are established. We would like to widely deliver new drugs to more patients through appropriate use of IMS technology and drug research and development.